Oral question asked in the House of Lords, by Lord Kamall (Conservative). It was answered on Tuesday, 22 July 2025.
Duchenne Muscular Dystrophy: Givinostat
- Question
-
My Lords, we heard from the noble Baroness, Lady Kramer, that there is an early access programme for a new treatment of Duchenne muscular dystrophy in the UK. Can the Minister share any intermediate observations or results from the early access programme? As the noble Baroness, Lady Kramer, asked, are there any plans to extend or expand it?
- Answer
-
I cannot comment on this case as the decision has not been made public yet; that would be completely inappropriate. If NICE does give its approval, the Secretary of State has committed to bringing it in. We are looking at ways in which we can get the medicines for rare diseases to which NICE gives its approval to where they are most needed as speedily as possible.
Secondary information
- Type
- Oral question
- Reference
- 848 c130
- Session
- 2024-26
- Oral question type
- Supplementary
- Chamber / Committee
- House of Lords chamber
- Subjects
- Muscular dystrophy Givinostat
- Link
- View this Oral question on hansard.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-06 00:09:12 +0100
- URI
- http://hansard.intranet.data.parliament.uk/Lords/2025-07-22/25072228000042
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2025-07-22/25072228000042
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2025-07-22/25072228000042